Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials.

ABSTRACT:

Objective

To compare the safety and efficacy of adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia.

Methods

Population

adult patients presenting with antipsychotic-induced hyperprolactinemia diagnosed by prolactin level with or without prolactin-related symptoms.

Interventions

adjunctive aripiprazole vs. adjunctive placebo.

Outcome measures

adverse events and efficacy of treatment.

Studies

randomized controlled trials.

Results

Five randomized controlled trials with a total of 639 patients (326 adjunctive aripiprazole, 313 adjunctive placebo) met the inclusion criteria. Adjunctive aripiprazole was associated with a 79.11% (125/158) prolactin level normalization rate. Meta-analysis of insomnia, headache, seda

SUBMITTER: Li X 

PROVIDER: S-EPMC3731351 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature